Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been reported in Graves' disease patients treated with antithyroid drugs (ATDs), especially propylthiouracil. ATD-induced ANCA-associated vasculitis usually involved the kidneys followed by the respiratory organs and skin. The treatment of ANCA-associated vasculitis induced by ATDs is to stop ATD therapy immediately, which often leads to an overall good prognosis. We report a case of ANCA-associated vasculitis in the peripheral nerves of the lower extremities in a 66-year-old woman who was treated with methimazole (MMI) for Graves' disease. To our knowledge, this is the third case of peripheral nervous system (PNS) involvement of ATD-induced vasculitis and the first case of PNS vasculitis associated with MMI.
Introduction
Antithyroid drugs (ATDs) including propylthiouracil (PTU), methimazole (MMI) and carbimazole (CMZ), a precursor of MMI, belong to the thionamide family, and are commonly used as first-line therapy for the management of Graves' disease (GD). Although ATDs are relatively safe, patients who are prescribed ATDs should be cautioned in regard to the potential side effects. These include rashes and joint pain, as well as major adverse effects such as agranulocytosis and hepatotoxicity, which typically occur early in the course of treatment. 1, 2) The side-effects of MMI are dose-dependent, whereas those of PTU do not show the same dose dependence. Vasculitis is the third most common major toxic reaction seen with ATD treatment, and is more often associated with PTU than with MMI. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis has also been reported in connection with ATDs, especially in Asian patients treated with PTU. The risk of developing ANCA-associated vasculitis is increased with time, in contrast to other adverse effects seen with ATDs. 2, 3) The clinical features of drug-induced ANCA-associated vasculitis are highly variable and include a variety of symptoms, such as fever, myalgia, arthralgia and flu-like syndrome, as well as demonstrating multisystem involvement most commonly involving the kidneys, respiratory tract and skin. Vessels in the joints, eyes, skeletal muscle, gastrointestinal tract and central and peripheral nerves may also be involved. 4) Although this syndrome generally resolves after drug cessation, high-dose glucocorticoid therapy or cyclophosphamide may be needed in severe cases.
3)
Here we describe a case of ANCA-associated vasculitis manifesting as peripheral neuropathy in the lower extremities in a GD patient taking MMI.
Case Report
A 66-year-old woman presented to our endo- ANCA-associated vasculitis is histologically characterized by inflammatory and necrotic processes that selectively affect the walls of small vessels such as small arteries and arterioles, capillaries and venules.
5)
Cases of ANCA-associated vasculitis are rare, but can be triggered by chemicals, infections and certain drugs. inforce the inflammatory events, leading to damage of the blood vessels. 5, 6) All ATDs can induce asymptomatic production of ANCA, but PTU is most often associated with ANCAassociated vasculitis. 7) A recent review including approximately 260 case reports of ANCA-associated vasculitis related to ATDs showed that 75% of these cases were associated with the use of PTU compared with only 25% with MMI. 5) The estimated incidence ANCA-associated vasculitis for PTU was calculated to be 39.2-times that for MMI. 8) The prevalence of ANCA-positive cases caused by ATDs varied between 4% and 64% for PTU (median 30%) and 0%
and 16% with MMI (median 6%). 5) During ATD administration in patients with GD, 21% of patients were found to be for ANCA positivity irrespective of the type of ATD administered. Only 15% of ANCA-positive patients who received ATD treatment actually presented with clinical manifestations of ANCA-associated vasculitis, corresponding to 3% of all GD patients who received ATD treatment. 5) The estimated annual incidence of ANCA-associated vasculitis by ATDs was between 0.53 and 0.79 patients per 10,000 people. 8) In addition, there was an overall trend between the onset of ANCA positivity and the duration of ATD administration. 5) The median time until onset of ANCAassociated vasculitis was 42 months after starting ATD treatment as a whole, specifically 39 months for PTU and 60 months for MMI. 8) The median dose at onset was 200 mg/day for PTU and 15 mg/day for MMI. 8) Clinical vasculitis was more frequent when the MPO-ANCA titers were high. There was a trend toward a decrease in ANCA titers after ATD discontinuation, although these titers remained positive in 40-60% of cases. 5) As GD is an autoimmune disease, it has a tendency to develop along with other autoimmune conditions. However, the prevalence of ANCA positivity in GD patients before initiating ATD therapy was shown to be between 0% to 13%, which was strikingly lower than the prevalence observed during (or after) ATD therapy. 5) Also, the presence of ANCAs in patients with GD before ATD treatment was predominantly with anti-bactericidal/permeability-increasing protein (BPI)-ANCA and anticathepsin-ANCA, and were different from the ANCAs, usually MPO-ANCA, that developed after initiating ATD therapy. 5 rologic manifestations than with idiopathic vasculitis. 7, 9) In addition, patients with ATD-induced vasculitis had more frequent skin manifestations, resulting in a shorter duration of symptoms before diagnosis. 7) In general, prognosis of ATD-induced vasculitis is good. All 56 patients with idiopathic vasculitis were treated with immunosuppressive therapy, of which six patients died during the first episode and 47 patients out of the remaining 50 had at least one relapse, while 16 ATD-treated patients stopped ATD treatment and only six patients were treated with immunosuppressive therapy with no disease relapse.
7)
The treatment of ANCA-associated vasculitis induced by ATDs is to stop ATD therapy immediately, which often leads to rapid clinical improvement and an overall good prognosis. When no improvement is observed after ATD withdrawal, the treatment is similar to those treatments for primary vasculitis in general, including high-dose glucocorticoids and immunosuppressive drugs such as cyclophosphamide and cyclosporine.
5)
Recent data highlight the mechanisms leading to ANCA-associated vasculitis secondary to the administration of ATD. 5 regressed upon drug withdrawal. 7) There have been two separate reports of cases of CNS vasculitis caused by MMI and PTU. 9, 11) In a series of 92
Japanese patients with ATD-induced vasculitis, three patients had CNS manifestations, all of whom were taking PTU, but none involved the peripheral nervous systems (PNS). 8) In addition, there were two reports of neurological system involvement by PTU-induced vasculitis. 12, 13) To the best of our knowledge, our case is the third case of PNS involvement and the first case of PNS involvement associated with MMI.
In conclusion, ATD-induced vasculitis is an extremely rare adverse effect with various clinical manifestations. Clinicians should be aware of this uncommon side effect of ATDs, which should be included in differential diagnosis. Early recognition of this adverse effect is important because immediate withdrawal of ATD is needed to prevent serious sequelae.
